The Motley Fool

PARA BIO FPO (ASX: PAR) Share Price and News

 Chart and Price Data

20mins delayed

Bid/Ask /
Avg Daily Volume
Day Movement
Day High/Low /
52 Week Range -
Year Return (Capital)
As at
Please Wait...


watch, watch list, observe, keep an eye on

5 small-cap shares I’m watching in FY 2020

Serko Ltd (ASX: SKO) and 4 other small-cap ASX companies worth watching in FY20. More »

invest chart up

Why Nufarm, Paradigm, ResApp, & Zip Co shares charged higher today

The Nufarm Limited (ASX:NUF) share price and the Zip Co Ltd (ASX:Z1P) share price are two of four charging higher... More »

bull vs bear

Paradigm reports “ground-breaking” osteoarthritis discovery: Is it the real deal?

Paradigm Biopharmaceuticals (ASX:PAR) is looking to partner with big pharma. More »

Winners Cup Trophy

Is Paradigm Biopharmaceuticals the share market’s next huge winner?

Paradigm: Buy the rumour, sell the news? More »

Why the Bionomics share price is up 40% today

Bionomics Ltd (ASX: BNO) looks very speculative. More »

Paradigm share price tanks despite positive clinical trial update

Paradigm Biopharmaceuticals Ltd (ASX: PAR) is a speccy biotech that could sink or soar. More »

Rocket soaring through the sky

Why the Mesoblast share price is going nuts today

Mesoblast limited (ASX: MSB) has signed an important partnership with Grünenthal. More »

bull and bear figurines facing off over stockmarket graph

Opthea share price lifts on clinical trial update: Is it a spec buy?

Opthea Ltd (ASX: OPT) is developing clinical treatments for eye diseases. More »

ASX shares higher

Why Ausdrill, Link, Paradigm, & Village Roadshow shares raced higher today

The Ausdrill Limited (ASX:ASL) share price and the Village Roadshow Ltd (ASX:VRL) share price are two of four racing higher on Thursday. Here's why... More »

Here’s why the Opthea share price is up 130% today

Opthea Ltd (ASX: OPT) has released positive Phase II results for its OPT-302 + Lucentis (ranibizumab) combination therapy. More »

Healthcare technology shares

Why Telix Pharmaceuticals shares are up 80% over the past year

Telix Pharmaceuticals is an oncology researcher with a renal cancer treatment at the Phase III stage. More »

Businessman paying Australian money

Biotech speccy Paradigm is being tipped for the big time

Paradigm (ASX: PAR) has $78 million cash on hand and a goal to commercialise osteoarthritis drugs. More »

bull vs bear

Why the Next Science share price has more than tripled in 2019

Next Science (ASX: NXS) and Paradigm (ASX: PAR) are two widely fancied speccy biotechs. More »

Paradigm Biopharmaceuticals share price higher on Ross River virus trial results

The Paradigm Biopharmaceuticals Ltd (ASX:PAR) share price has stormed higher this morning after announcing the results of a Ross River virus trial... More »